Clinical Trials Logo

Clinical Trial Summary

Heart disease is the number one cause of death in the United States, with over 650,000 deaths in 2019 alone. Many healthy individuals possess key risk factors for heart disease which include but are not limited to high blood pressure, high cholesterol, family history of heart disease, and diabetes. The Mason Heart Study-MCG (MHS-MCG) registry is designed to collect magnetocardiography (MCG) scans on a select group of healthy volunteers who work for the city of Mason, OH, with and without cardiac symptoms, illnesses, and/or risk factors. CardioFlux is used as a noninvasive MCG tool that analyzes and records the magnetic fields of the heart to detect various forms of heart disease. There will be a 12-month duration of the study where we propose to collect screening data from approximately 250 volunteers who present to the Genetesis facility for a 5-minute CardioFlux MCG scan. The volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04732975
Study type Observational
Source Genetesis Inc.
Contact
Status Suspended
Phase
Start date December 14, 2020
Completion date June 2024

See also
  Status Clinical Trial Phase
Completed NCT04739267 - Acute Coronary Syndrome CardioFlux TM Study (ACCMED)